Why NRX Pharmaceuticals Stock Is Surging Today

NRX Pharmaceuticals Inc NRXP is trading significantly higher Thursday after the company announced the Journal of Infectious Diseases and Treatment published trial data of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure.

The study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the Houston Methodist Hospital.

"Although randomized, placebo-controlled trials are the gold standard for medical evidence, the findings in this open-label study are remarkably similar to those seen at tertiary care medical centers in the phase 2b/3 trial of aviptadil vs. placebo. Therefore, we view this study as supportive evidence that aviptadil protects the lung against the lethal effects of the SARS-CoV-2 virus," said Jihad Georges Youssef, lead author of the study and medical director of the advanced lung diseases program at Houston Methodist J. C. Walter Jr. Transplant Center.

NRX Pharmaceuticals is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

NRXP Price Action: NRX Pharmaceuticals has traded as high as $26.24 and as low as $6.42 over a 52-week period.

The stock was up 23.5% at $11.65 at time of publication.